In 2017 Shaker co-founded GTN Ltd (Generative Tensorial Networks), a startup aiming to combine quantum computing and AI for drug discovery. Shaker stepped down from her role as CEO of the company in August 2019, shortly before the company entered liquidation. The company aimed to combine machine learning techniques and quantum physics simulations in order to predict better therapeutics for medical use.[8][9] Combining artificial intelligence with quantum models of published molecular structures may prove a novel and effective method to predict binding partners to disease regulators.[9]